Farley Brian E

SEC source: 0001192482-20-000646 · edgar.xml · nonDerivative · entry 1

Farley Brian E · CIK 0001306117 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 265,748

F1 · shares: Represents a restricted stock unit ("RSU") award that vests on the earlier of (a) August 5, 2021, and (b) the Company's next annual meeting of stockholders, in each case subject to continuous service of the Reporting Person through such date.

F2 · price: Each RSU respresents a contingent right to receive one share of the Issuer's common stock.

SEC source: 0001192482-20-000406 · edgar.xml · nonDerivative · entry 1

Farley Brian E · CIK 0001306117 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 242,606

F1 · shares: Represents a restricted stock unit ("RSU") award that vests on the earlier of (a) May 26, 2021, and (b) the Company's next annual meeting of stockholders, in each case subject to continuous service of the Reporting Person through such date.

F2 · price: Each RSU respresents a contingent right to receive one share of the Issuer's common stock.

SEC source: 0001192482-20-000236 · edgar.xml · nonDerivative · entry 2

Farley Brian E · CIK 0001306117 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 217,606

F2 · price: Represents the weighted average purchase price. The highest price at which shares were purchased was $2.35 and the lowest price at which shares were purchased was $2.20. The Reporting Person undertakes to provide upon request by the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares purchased at each separate price for all transactions reported on this Form 4.

SEC source: 0001192482-20-000236 · edgar.xml · nonDerivative · entry 1

Farley Brian E · CIK 0001306117 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 177,606

F1 · price: Represents the weighted average purchase price. The highest price at which shares were purchased was $2.18 and the lowest price at which shares were purchased was $2.16. The Reporting Person undertakes to provide upon request by the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares purchased at each separate price for all transactions reported on this Form 4.

SEC source: 0001192482-20-000202 · edgar.xml · nonDerivative · entry 1

Farley Brian E · CIK 0001306117 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 167,606

F1 · shares: Represents a restricted stock unit ("RSU") award which shall vest on the first anniversary of the date of grant, subject to continuous service of the Reporting Person through such date.

F2 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock.

SEC source: 0001209191-19-057051 · doc4.xml · nonDerivative · entry 2

Farley Brian E · CIK 0001306117 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 147,606

F2 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.25 to $4.28 inclusive.

SEC source: 0001209191-19-057051 · doc4.xml · nonDerivative · entry 1

Farley Brian E · CIK 0001306117 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 136,606

F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.5824 to $4.6174 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnotes (1) and (2).

SEC source: 0001209191-19-033452 · doc4.xml · derivative · entry 2

Farley Brian E · CIK 0001306117 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,347

Underlying: Common Stock · 7,347 shares

Expires 2029-05-27

F3 · derivative.exercise_date: The option shall vest on the earlier of (a) May 28, 2029, and (b) the Company's next annual meeting of stockholders, in each case subject to continuous service of the Reporting Person through such date.

SEC source: 0001209191-19-033452 · doc4.xml · nonDerivative · entry 1

Farley Brian E · CIK 0001306117 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 117,606

F1 · shares: Represents a restricted stock unit ("RSU") award that vests on the earlier of (a) May 28, 2029, and (b) the Company's next annual meeting of stockholders, in each case subject to continuous service of the Reporting Person through such date.

F2 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock.

SEC source: 0001209191-19-026015 · doc4.xml · nonDerivative · entry 1

Farley Brian E · CIK 0001306117 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 112,022

F1 · kind: Represents a restricted stock unit ("RSU") award. The RSUs will vest on the earlier of July 26, 2019 or the date of the Issuer's 2019 annual meeting of stockholders, subject to the Reporting Person's continued service.

F2 · price: Each RSU represents the contingent right to receive one share of the Issuer's common stock.

SEC source: 0001209191-18-041640 · doc4.xml · derivative · entry 9

Farley Brian E · CIK 0001306117 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,959

Underlying: Common Stock · 10,959 shares

Expires 2028-04-25

F2 · derivative.exercise_date: The performance criterion for vesting of this option was met upon the closing of the Issuer's initial public offering. One twelfth (1/12th) of the shares subject to the option vested or shall vest monthly commencing on March 16, 2018, subject to Reporting Person continuing to provide service through each such date.

SEC source: 0001209191-18-041640 · doc4.xml · derivative · entry 8

Farley Brian E · CIK 0001306117 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 1,506 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each share of Series D Convertible Preferred Stock, Series E Convertible Preferred Stock, Series F Convertible Preferred Stock and Series G Convertible Preferred Stock was convertible at any time, at the option of the holder, into Common Stock, on a one-for-one basis, had no expiration date and converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering.

F1 · derivative.exercise_date: Each share of Series D Convertible Preferred Stock, Series E Convertible Preferred Stock, Series F Convertible Preferred Stock and Series G Convertible Preferred Stock was convertible at any time, at the option of the holder, into Common Stock, on a one-for-one basis, had no expiration date and converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering.

F1 · derivative.expiration_date: Each share of Series D Convertible Preferred Stock, Series E Convertible Preferred Stock, Series F Convertible Preferred Stock and Series G Convertible Preferred Stock was convertible at any time, at the option of the holder, into Common Stock, on a one-for-one basis, had no expiration date and converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering.

SEC source: 0001209191-18-041640 · doc4.xml · derivative · entry 7

Farley Brian E · CIK 0001306117 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 9,525 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each share of Series D Convertible Preferred Stock, Series E Convertible Preferred Stock, Series F Convertible Preferred Stock and Series G Convertible Preferred Stock was convertible at any time, at the option of the holder, into Common Stock, on a one-for-one basis, had no expiration date and converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering.

F1 · derivative.exercise_date: Each share of Series D Convertible Preferred Stock, Series E Convertible Preferred Stock, Series F Convertible Preferred Stock and Series G Convertible Preferred Stock was convertible at any time, at the option of the holder, into Common Stock, on a one-for-one basis, had no expiration date and converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering.

F1 · derivative.expiration_date: Each share of Series D Convertible Preferred Stock, Series E Convertible Preferred Stock, Series F Convertible Preferred Stock and Series G Convertible Preferred Stock was convertible at any time, at the option of the holder, into Common Stock, on a one-for-one basis, had no expiration date and converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering.

SEC source: 0001209191-18-041640 · doc4.xml · derivative · entry 6

Farley Brian E · CIK 0001306117 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 15,342 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each share of Series D Convertible Preferred Stock, Series E Convertible Preferred Stock, Series F Convertible Preferred Stock and Series G Convertible Preferred Stock was convertible at any time, at the option of the holder, into Common Stock, on a one-for-one basis, had no expiration date and converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering.

F1 · derivative.exercise_date: Each share of Series D Convertible Preferred Stock, Series E Convertible Preferred Stock, Series F Convertible Preferred Stock and Series G Convertible Preferred Stock was convertible at any time, at the option of the holder, into Common Stock, on a one-for-one basis, had no expiration date and converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering.

F1 · derivative.expiration_date: Each share of Series D Convertible Preferred Stock, Series E Convertible Preferred Stock, Series F Convertible Preferred Stock and Series G Convertible Preferred Stock was convertible at any time, at the option of the holder, into Common Stock, on a one-for-one basis, had no expiration date and converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering.

SEC source: 0001209191-18-041640 · doc4.xml · derivative · entry 5

Farley Brian E · CIK 0001306117 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 8,483 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each share of Series D Convertible Preferred Stock, Series E Convertible Preferred Stock, Series F Convertible Preferred Stock and Series G Convertible Preferred Stock was convertible at any time, at the option of the holder, into Common Stock, on a one-for-one basis, had no expiration date and converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering.

F1 · derivative.exercise_date: Each share of Series D Convertible Preferred Stock, Series E Convertible Preferred Stock, Series F Convertible Preferred Stock and Series G Convertible Preferred Stock was convertible at any time, at the option of the holder, into Common Stock, on a one-for-one basis, had no expiration date and converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering.

F1 · derivative.expiration_date: Each share of Series D Convertible Preferred Stock, Series E Convertible Preferred Stock, Series F Convertible Preferred Stock and Series G Convertible Preferred Stock was convertible at any time, at the option of the holder, into Common Stock, on a one-for-one basis, had no expiration date and converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering.

SEC source: 0001209191-18-041640 · doc4.xml · nonDerivative · entry 4

Farley Brian E · CIK 0001306117 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 110,438

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each share of Series D Convertible Preferred Stock, Series E Convertible Preferred Stock, Series F Convertible Preferred Stock and Series G Convertible Preferred Stock was convertible at any time, at the option of the holder, into Common Stock, on a one-for-one basis, had no expiration date and converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering.

SEC source: 0001209191-18-041640 · doc4.xml · nonDerivative · entry 3

Farley Brian E · CIK 0001306117 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 108,932

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each share of Series D Convertible Preferred Stock, Series E Convertible Preferred Stock, Series F Convertible Preferred Stock and Series G Convertible Preferred Stock was convertible at any time, at the option of the holder, into Common Stock, on a one-for-one basis, had no expiration date and converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering.

SEC source: 0001209191-18-041640 · doc4.xml · nonDerivative · entry 2

Farley Brian E · CIK 0001306117 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 99,407

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each share of Series D Convertible Preferred Stock, Series E Convertible Preferred Stock, Series F Convertible Preferred Stock and Series G Convertible Preferred Stock was convertible at any time, at the option of the holder, into Common Stock, on a one-for-one basis, had no expiration date and converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering.

SEC source: 0001209191-18-041640 · doc4.xml · nonDerivative · entry 1

Farley Brian E · CIK 0001306117 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 84,065

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each share of Series D Convertible Preferred Stock, Series E Convertible Preferred Stock, Series F Convertible Preferred Stock and Series G Convertible Preferred Stock was convertible at any time, at the option of the holder, into Common Stock, on a one-for-one basis, had no expiration date and converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering.

SEC source: 0001235802-18-000019 · primary_doc.xml · derivative · entry 7

Farley Brian E · CIK 0001306117 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 5,000 shares

Expires 2027-06-13

F7 · derivative.exercise_date: This option, which provided for vesting in full on the earlier of June 13, 2018 and the date of the annual stockholder meeting following June 13, 2017, was canceled in the merger in exchange for a cash payment equal to: (a) the number of shares of Issuer common stock underlying the option, multiplied by (b) the excess of $24.00 over the per share exercise price of such option.

SEC source: 0001235802-18-000019 · primary_doc.xml · derivative · entry 6

Farley Brian E · CIK 0001306117 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 10,000 shares

Expires 2026-06-14

F6 · derivative.exercise_date: This option, which provided for vesting in full on the earlier of June 14, 2017 and the date of the annual stockholder meeting following June 14, 2016, was canceled in the merger in exchange for a cash payment equal to: (a) the number of shares of Issuer common stock underlying the option, multiplied by (b) the excess of $24.00 over the per share exercise price of such option.

SEC source: 0001235802-18-000019 · primary_doc.xml · derivative · entry 5

Farley Brian E · CIK 0001306117 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 188,800 shares

Expires 2024-12-16

F5 · derivative.exercise_date: This option, which provided for vesting in 48 equal monthly installments commencing on December 1, 2014, was canceled in the merger in exchange for a cash payment equal to: (a) the number of shares of Issuer common stock underlying the option, multiplied by (b) the excess of $24.00 over the per share exercise price of such option.

SEC source: 0001235802-18-000019 · primary_doc.xml · derivative · entry 4

Farley Brian E · CIK 0001306117 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 34,510 shares

Expires 2023-03-19

F4 · derivative.exercise_date: This option, which was fully vested on January 1, 2017, was canceled in the merger in exchange for a cash payment equal to: (a) the number of shares of Issuer common stock underlying the option, multiplied by (b) the excess of $24.00 over the per share exercise price of such option.

SEC source: 0001235802-18-000019 · primary_doc.xml · derivative · entry 3

Farley Brian E · CIK 0001306117 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 28,439 shares

Expires 2022-02-08

F3 · derivative.exercise_date: This option, which was fully vested on December 31, 2015, was canceled in the merger in exchange for a cash payment equal to: (a) the number of shares of Issuer common stock underlying the option, multiplied by (b) the excess of $24.00 over the per share exercise price of such option.

SEC source: 0001235802-18-000019 · primary_doc.xml · derivative · entry 2

Farley Brian E · CIK 0001306117 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 39,563 shares

Expires 2020-03-24

F2 · derivative.exercise_date: This option, which was fully vested on January 1, 2014, was canceled in the merger in exchange for a cash payment equal to: (a) the number of shares of Issuer common stock underlying the option, multiplied by (b) the excess of $24.00 over the per share exercise price of such option.

SEC source: 0001235802-18-000019 · primary_doc.xml · nonDerivative · entry 1

Farley Brian E · CIK 0001306117 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

F1 · price: Disposed of pursuant to an Agreement and Plan of Merger, dated December 7, 2017, between Entellus Medical, Inc., Stryker Corporation and Explorer Merger Sub Corp. in exchange for a cash payment of $24.00 per share.

SEC source: 0001686266-17-000019 · primary_doc.xml · nonDerivative · entry 1

Farley Brian E · CIK 0001306117 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 291,743

F1 · kind: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended.

F2 · balance_after: Includes 2,500 shares that will be issued over time upon vesting pursuant to a restricted stock unit granted under the Entellus Medical, Inc. 2015 Incentive Award Plan.

SEC source: 0001235802-17-000156 · primary_doc.xml · nonDerivative · entry 4

Farley Brian E · CIK 0001306117 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 393,062

F1 · kind: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended.

F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.10 to $20.195, inclusive. The reporting person undertakes to provide to Entellus Medical, Inc., any security holder of Entellus Medical, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (5) to this Form 4.

F2 · balance_after: Includes 2,500 shares that will be issued over time upon vesting pursuant to a restricted stock unit granted under the Entellus Medical, Inc. 2015 Incentive Award Plan.

SEC source: 0001235802-17-000156 · primary_doc.xml · nonDerivative · entry 3

Farley Brian E · CIK 0001306117 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 413,062

F1 · kind: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended.

F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.60 to $19.725, inclusive. The reporting person undertakes to provide to Entellus Medical, Inc., any security holder of Entellus Medical, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (4) to this Form 4.

F2 · balance_after: Includes 2,500 shares that will be issued over time upon vesting pursuant to a restricted stock unit granted under the Entellus Medical, Inc. 2015 Incentive Award Plan.

SEC source: 0001235802-17-000156 · primary_doc.xml · nonDerivative · entry 2

Farley Brian E · CIK 0001306117 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 423,062

F1 · kind: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.10 to $19.385, inclusive. The reporting person undertakes to provide to Entellus Medical, Inc., any security holder of Entellus Medical, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (3) to this Form 4.

F2 · balance_after: Includes 2,500 shares that will be issued over time upon vesting pursuant to a restricted stock unit granted under the Entellus Medical, Inc. 2015 Incentive Award Plan.

SEC source: 0001235802-17-000156 · primary_doc.xml · nonDerivative · entry 1

Farley Brian E · CIK 0001306117 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 429,090

F1 · kind: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended.

F2 · balance_after: Includes 2,500 shares that will be issued over time upon vesting pursuant to a restricted stock unit granted under the Entellus Medical, Inc. 2015 Incentive Award Plan.

SEC source: 0001235802-17-000081 · primary_doc.xml · derivative · entry 2

Farley Brian E · CIK 0001306117 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,000

Underlying: Common Stock · 5,000 shares

Expires 2027-06-13

F2 · derivative.exercise_date: This option vests in full on the earlier to occur of June 13, 2018 and the date of the Company's annual meeting of stockholders immediately following June 13, 2017, subject to the Reporting Person's continued service with the Company through the applicable vesting date.

SEC source: 0001235802-17-000081 · primary_doc.xml · nonDerivative · entry 1

Farley Brian E · CIK 0001306117 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 433,062

F1 · shares: Includes 2,500 shares that will be issued over time upon vesting pursuant to a restricted stock unit granted under the Entellus Medical, Inc. 2015 Incentive Award Plan.

F1 · balance_after: Includes 2,500 shares that will be issued over time upon vesting pursuant to a restricted stock unit granted under the Entellus Medical, Inc. 2015 Incentive Award Plan.

SEC source: 0001235802-17-000017 · primary_doc.xml · nonDerivative · entry 1

Farley Brian E · CIK 0001306117 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 430,562

F1 · kind: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.11 to $20.22, inclusive. The reporting person undertakes to provide to Entellus Medical, Inc., any security holder of Entellus Medical, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) to this Form 4.

SEC source: 0001235802-17-000012 · primary_doc.xml · nonDerivative · entry 2

Farley Brian E · CIK 0001306117 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 444,581

F1 · kind: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.10 to $19.11, inclusive. The reporting person undertakes to provide to Entellus Medical, Inc., any security holder of Entellus Medical, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (3) to this Form 4.

SEC source: 0001235802-17-000012 · primary_doc.xml · nonDerivative · entry 1

Farley Brian E · CIK 0001306117 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 449,423

F1 · kind: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.10 to $19.12, inclusive. The reporting person undertakes to provide to Entellus Medical, Inc., any security holder of Entellus Medical, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) to this Form 4.

SEC source: 0001235802-17-000003 · primary_doc.xml · nonDerivative · entry 2

Farley Brian E · CIK 0001306117 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 454,423

F1 · kind: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended.

SEC source: 0001235802-17-000003 · primary_doc.xml · nonDerivative · entry 1

Farley Brian E · CIK 0001306117 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 454,581

F1 · kind: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.68 to $18.88, inclusive. The reporting person undertakes to provide to Entellus Medical, Inc., any security holder of Entellus Medical, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) to this Form 4.

SEC source: 0001686266-16-000005 · primary_doc.xml · nonDerivative · entry 3

Farley Brian E · CIK 0001306117 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 475,581

F1 · kind: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended.

SEC source: 0001686266-16-000005 · primary_doc.xml · nonDerivative · entry 2

Farley Brian E · CIK 0001306117 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 476,330

F1 · kind: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended.

SEC source: 0001686266-16-000005 · primary_doc.xml · nonDerivative · entry 1

Farley Brian E · CIK 0001306117 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 477,249

F1 · kind: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended.

SEC source: 0001235802-16-000327 · primary_doc.xml · nonDerivative · entry 3

Farley Brian E · CIK 0001306117 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 479,581

F1 · kind: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended.

SEC source: 0001235802-16-000327 · primary_doc.xml · nonDerivative · entry 2

Farley Brian E · CIK 0001306117 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 483,929

F1 · kind: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended.

SEC source: 0001235802-16-000327 · primary_doc.xml · nonDerivative · entry 1

Farley Brian E · CIK 0001306117 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 484,581

F1 · kind: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.31 to $18.69, inclusive. The reporting person undertakes to provide to Entellus Medical, Inc., any security holder of Entellus Medical, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) to this Form 4.

SEC source: 0001235802-16-000324 · primary_doc.xml · nonDerivative · entry 1

Farley Brian E · CIK 0001306117 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 494,581

F1 · kind: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended.

SEC source: 0001235802-16-000323 · primary_doc.xml · nonDerivative · entry 1

Farley Brian E · CIK 0001306117 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 499,581

F1 · kind: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended.

SEC source: 0001235802-16-000321 · primary_doc.xml · nonDerivative · entry 2

Farley Brian E · CIK 0001306117 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 504,581

F1 · kind: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended.

SEC source: 0001235802-16-000321 · primary_doc.xml · nonDerivative · entry 1

Farley Brian E · CIK 0001306117 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 509,581

F1 · kind: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended.

SEC source: 0001235802-16-000313 · primary_doc.xml · nonDerivative · entry 1

Farley Brian E · CIK 0001306117 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 514,581

F1 · kind: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.25 to $22.50, inclusive. The reporting person undertakes to provide to Entellus Medical, Inc., any security holder of Entellus Medical, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) to this Form 4.

SEC source: 0001235802-16-000299 · primary_doc.xml · nonDerivative · entry 1

Farley Brian E · CIK 0001306117 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 544,581

F1 · kind: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.60 to $18.90, inclusive. The reporting person undertakes to provide to Entellus Medical, Inc., any security holder of Entellus Medical, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) to this Form 4.